The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma
We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatm...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer care 2015-01, Vol.24 (1), p.117-124 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 124 |
|---|---|
| container_issue | 1 |
| container_start_page | 117 |
| container_title | European journal of cancer care |
| container_volume | 24 |
| creator | Law, M.F. Lai, H.K. Chan, H.N. Ha, C.Y. Ng, C. Yeung, Y.M. Yip, S.F. |
| description | We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg‐positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg‐positive group and 65 in the HBsAg‐negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg‐positive group vs. 54% in HBsAg‐negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg‐positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy. |
| doi_str_mv | 10.1111/ecc.12166 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1672091264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1672091264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4956-2bad02bf0ee12351b28c78f0b6c4201f1fa2c51ccebb7ed7cb910b315f5be3fb3</originalsourceid><addsrcrecordid>eNqNkc9vFCEUx4nR2LV68B8wJF7qYVoeDMxwdDftVtNqYqoeCbAPlzo_tsOMdf972W7bQ08SEl7C50N470vIW2DHkNcJen8MHJR6RmYglCy4kOVzMmNaQSFLLg7Iq5SuGQMBunxJDrisy1rpekbS1RppbDfWj7QPdI0bO8YxJjqnf-IwJXp0Pv_xgcYuoB9j39G8fRO76G1D-2n0fYtpZ-487MZEb-O4pqsYwpSQNnb4hXReeGwa2mzbzbpv7WvyItgm4Zv785B8Pzu9WpwXF1-XnxYfLwpfaqkK7uyKcRcYIuSGwPHaV3VgTvmSMwgQLPcSvEfnKlxV3mlgToAM0qEIThySo_27m6G_mTCNpo1p9xPbYT8lA6riTANX5X-gslRKa11n9P0T9Lqfhi43kimhuaiF0Jl6d09NrsWV2QyxtcPWPEw-Ayd74DY2uH28B2Z2kZocqbmL1JwuFndFNoq9EdOIfx8NO_w2qhKVND-_LM23Ci6XZ58vDRP_AOW_oZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1639238339</pqid></control><display><type>article</type><title>The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Law, M.F. ; Lai, H.K. ; Chan, H.N. ; Ha, C.Y. ; Ng, C. ; Yeung, Y.M. ; Yip, S.F.</creator><creatorcontrib>Law, M.F. ; Lai, H.K. ; Chan, H.N. ; Ha, C.Y. ; Ng, C. ; Yeung, Y.M. ; Yip, S.F.</creatorcontrib><description>We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg‐positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg‐positive group and 65 in the HBsAg‐negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg‐positive group vs. 54% in HBsAg‐negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg‐positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy.</description><identifier>ISSN: 0961-5423</identifier><identifier>EISSN: 1365-2354</identifier><identifier>DOI: 10.1111/ecc.12166</identifier><identifier>PMID: 25848698</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-HIV Agents - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Chemotherapy ; Clinical outcomes ; diffuse large B-cell lymphoma ; Female ; Hepatitis ; hepatitis B ; Hepatitis B - complications ; Hepatitis B - prevention & control ; Hepatitis B virus ; Hepatitis B virus - isolation & purification ; Humans ; Infections ; Lamivudine - therapeutic use ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - complications ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Male ; Medical prognosis ; Middle Aged ; Nursing ; Prognosis ; Retrospective Studies ; Risk Factors ; Rituximab - adverse effects ; Rituximab - therapeutic use ; Survival Analysis ; Treatment Outcome ; Young Adult</subject><ispartof>European journal of cancer care, 2015-01, Vol.24 (1), p.117-124</ispartof><rights>2013 John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons Ltd.</rights><rights>Copyright © 2015 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4956-2bad02bf0ee12351b28c78f0b6c4201f1fa2c51ccebb7ed7cb910b315f5be3fb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fecc.12166$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fecc.12166$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25848698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Law, M.F.</creatorcontrib><creatorcontrib>Lai, H.K.</creatorcontrib><creatorcontrib>Chan, H.N.</creatorcontrib><creatorcontrib>Ha, C.Y.</creatorcontrib><creatorcontrib>Ng, C.</creatorcontrib><creatorcontrib>Yeung, Y.M.</creatorcontrib><creatorcontrib>Yip, S.F.</creatorcontrib><title>The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma</title><title>European journal of cancer care</title><addtitle>Eur J Cancer Care (Engl)</addtitle><description>We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg‐positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg‐positive group and 65 in the HBsAg‐negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg‐positive group vs. 54% in HBsAg‐negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg‐positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>diffuse large B-cell lymphoma</subject><subject>Female</subject><subject>Hepatitis</subject><subject>hepatitis B</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - isolation & purification</subject><subject>Humans</subject><subject>Infections</subject><subject>Lamivudine - therapeutic use</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - complications</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Nursing</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Rituximab - adverse effects</subject><subject>Rituximab - therapeutic use</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0961-5423</issn><issn>1365-2354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9vFCEUx4nR2LV68B8wJF7qYVoeDMxwdDftVtNqYqoeCbAPlzo_tsOMdf972W7bQ08SEl7C50N470vIW2DHkNcJen8MHJR6RmYglCy4kOVzMmNaQSFLLg7Iq5SuGQMBunxJDrisy1rpekbS1RppbDfWj7QPdI0bO8YxJjqnf-IwJXp0Pv_xgcYuoB9j39G8fRO76G1D-2n0fYtpZ-487MZEb-O4pqsYwpSQNnb4hXReeGwa2mzbzbpv7WvyItgm4Zv785B8Pzu9WpwXF1-XnxYfLwpfaqkK7uyKcRcYIuSGwPHaV3VgTvmSMwgQLPcSvEfnKlxV3mlgToAM0qEIThySo_27m6G_mTCNpo1p9xPbYT8lA6riTANX5X-gslRKa11n9P0T9Lqfhi43kimhuaiF0Jl6d09NrsWV2QyxtcPWPEw-Ayd74DY2uH28B2Z2kZocqbmL1JwuFndFNoq9EdOIfx8NO_w2qhKVND-_LM23Ci6XZ58vDRP_AOW_oZA</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Law, M.F.</creator><creator>Lai, H.K.</creator><creator>Chan, H.N.</creator><creator>Ha, C.Y.</creator><creator>Ng, C.</creator><creator>Yeung, Y.M.</creator><creator>Yip, S.F.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>8FD</scope><scope>ASE</scope><scope>FPQ</scope><scope>FR3</scope><scope>K6X</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma</title><author>Law, M.F. ; Lai, H.K. ; Chan, H.N. ; Ha, C.Y. ; Ng, C. ; Yeung, Y.M. ; Yip, S.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4956-2bad02bf0ee12351b28c78f0b6c4201f1fa2c51ccebb7ed7cb910b315f5be3fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>diffuse large B-cell lymphoma</topic><topic>Female</topic><topic>Hepatitis</topic><topic>hepatitis B</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - isolation & purification</topic><topic>Humans</topic><topic>Infections</topic><topic>Lamivudine - therapeutic use</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - complications</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Nursing</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Rituximab - adverse effects</topic><topic>Rituximab - therapeutic use</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Law, M.F.</creatorcontrib><creatorcontrib>Lai, H.K.</creatorcontrib><creatorcontrib>Chan, H.N.</creatorcontrib><creatorcontrib>Ha, C.Y.</creatorcontrib><creatorcontrib>Ng, C.</creatorcontrib><creatorcontrib>Yeung, Y.M.</creatorcontrib><creatorcontrib>Yip, S.F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Technology Research Database</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Engineering Research Database</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Law, M.F.</au><au>Lai, H.K.</au><au>Chan, H.N.</au><au>Ha, C.Y.</au><au>Ng, C.</au><au>Yeung, Y.M.</au><au>Yip, S.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma</atitle><jtitle>European journal of cancer care</jtitle><addtitle>Eur J Cancer Care (Engl)</addtitle><date>2015-01</date><risdate>2015</risdate><volume>24</volume><issue>1</issue><spage>117</spage><epage>124</epage><pages>117-124</pages><issn>0961-5423</issn><eissn>1365-2354</eissn><abstract>We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg‐positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg‐positive group and 65 in the HBsAg‐negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg‐positive group vs. 54% in HBsAg‐negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg‐positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25848698</pmid><doi>10.1111/ecc.12166</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-5423 |
| ispartof | European journal of cancer care, 2015-01, Vol.24 (1), p.117-124 |
| issn | 0961-5423 1365-2354 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1672091264 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-HIV Agents - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols Chemotherapy Clinical outcomes diffuse large B-cell lymphoma Female Hepatitis hepatitis B Hepatitis B - complications Hepatitis B - prevention & control Hepatitis B virus Hepatitis B virus - isolation & purification Humans Infections Lamivudine - therapeutic use Lymphoma Lymphoma, Large B-Cell, Diffuse - complications Lymphoma, Large B-Cell, Diffuse - drug therapy Male Medical prognosis Middle Aged Nursing Prognosis Retrospective Studies Risk Factors Rituximab - adverse effects Rituximab - therapeutic use Survival Analysis Treatment Outcome Young Adult |
| title | The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A19%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20hepatitis%20B%20virus%20(HBV)%20infection%20on%20clinical%20outcomes%20of%20patients%20with%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=European%20journal%20of%20cancer%20care&rft.au=Law,%20M.F.&rft.date=2015-01&rft.volume=24&rft.issue=1&rft.spage=117&rft.epage=124&rft.pages=117-124&rft.issn=0961-5423&rft.eissn=1365-2354&rft_id=info:doi/10.1111/ecc.12166&rft_dat=%3Cproquest_pubme%3E1672091264%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1639238339&rft_id=info:pmid/25848698&rfr_iscdi=true |